Parkinson’s Disease is a relentless adversary for the human body, and over 10 million people worldwide fight a daily battle against it. Despite more than 65 years of research, current therapies sill only provide symptomatic relief. Join us as our expert panel discusses why Parkinson’s […]
Seth Ettenberg and Nick discuss how technology is used to develop regenerative medicine for conditions such as Parkinson’s disease and Alzheimer’s disease. Seth Ettenberg is CEO and President of BlueRock Therapeutics, a wholly owned subsidiary of Bayer. He’s a biotech entrepreneur, on the cutting […]
BlueRock Therapeutics’ President and CEO Seth Ettenberg, Ph.D. talks to Cell & Gene: The Podcast listeners about the company’s Phase 1 Clinical Trial for Advanced Parkinson’s Disease. Ettenberg also covers the most promising therapeutic applications for iPSCs currently in development as well as the […]
